Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 0615-8329

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 0615-8329). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ncs Healthcare Of Ky, Llc Dba Vangard Labs, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Divalproex Sodium Er Tabs 8329 1

Chemical structure of divalproex sodium, depicting its molecular arrangement including sodium, carbon, oxygen, and hydrogen atoms with indicated bonds and groups.*

FDA Label Image

Divalproex Sodium Er Tabs 8329 2

A line graph comparing the percent reduction in CPS rate between Divalproex Sodium delayed-release tablets and placebo. The y-axis shows percent reduction in CPS rate, with improvement upward and worsening downward, while the x-axis represents the percent of patients. Solid line represents Divalproex Sodium, dashed line represents placebo, showing superior CPS rate reduction with Divalproex Sodium over placebo.*

FDA Label Image

Divalproex Sodium Er Tabs 8329 3

A cumulative distribution plot comparing the percentage reduction in CPS rate for high dose versus low dose Divalproex Sodium delayed-release tablets. The vertical axis shows the percentage reduction in CPS rate, with improvement upward and worsening downward. The horizontal axis represents the percentage of patients, decreasing from 100% to 0%. Two curves illustrate patient response distributions for high dose (solid line) and low dose (dashed line) formulations.*

FDA Label Image

Divalproex Sodium Er Tabs 8329 4

A bar chart comparing two groups: Placebo and Divalproex Sodium Extended-Release Tablets. The vertical axis likely represents a measured value with the placebo bar reaching 0.6 and the Divalproex Sodium bar reaching approximately 1.2, indicating a higher value for the Divalproex Sodium group.*

FDA Label Image

Divalproex Sodium Er Tabs 8329 5

Divalproex Sodium Extended-release Tablets, USP 250 mg, film-coated, packaged in a bottle of 30. Manufactured by Dr. Reddy's and labeled by NCS HealthCare of KY, LLC dba Vangard Labs in Glasgow, KY. Includes storage instructions, dosing information, and multiple barcode labels. The label is marked for institutional use only and notes that each tablet contains divalproex sodium equivalent to 250 mg valproic acid.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.